Whatsapp

Medical Professionals

Refer a patient

The Medical Research Center offers Doctors the possibility of referring patients to be incorporated into research protocols.

We will maintain direct and fluid contact with you to keep you informed about the evolution of your patients from the moment of their initial evaluation.

For more information:

Active Studies Recruiting Patients

Cardiology Area

EASi-HF

RECRUITING

“A parallel-group, randomized, double-blind, phase III superiority trial to evaluate the efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared to placebo and empagliflozin in patients with heart failure (HF) classes II to IV) and left ventricular ejection fraction (LVEF) ≥40%.”

EASi-HF Reduced

RECRUITING

Protocol Title: EASi-HF Reduced: A Phase III, Double-Blind, Randomized, Parallel-Group Superiority Trial to Evaluate the Efficacy and Safety of Combined Use of Oral BI 690517 and Empagliflozin Compared to Placebo and Empagliflozin in Participants with Symptomatic Chronic Heart Failure (CI: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) < 40%

J2O-MC-EKBG

RECRUITING

Phase 3, randomized, double-blind, placebo-controlled study to investigate the effect of Muvalaplin on reducing major adverse cardiovascular events in adults with elevated lipoprotein(a) who have had a previous atherosclerotic cardiovascular event or are at risk of suffering a first atherosclerotic cardiovascular event - MOVE-Lp(a)

ATTAIN

RECRUITING

Protocol title: A phase 3, randomized, double-blind, placebo-controlled, event-based study to investigate the effect of orforglipron on the incidence of major adverse cardiovascular events in participants with established atherosclerotic cardiovascular disease or chronic kidney disease (ATTAIN-Outcomes)

BalanceD-HF

RECRUITING

"A phase III, randomized, double-blind study to evaluate the effect of balcinrenone/dapagliflozin, compared with dapagliflozin, on the risk of heart failure events and cardiovascular death in patients with heart failure and impaired renal function (BalanceD-HF)"

BaxDuo PREVENT HF

RECRUITING

Phase III study to investigate the risk of heart failure and cardiovascular death with Baxdrostat in combination with dapagliflozin in participants at increased risk of developing heart failure.

Enith 2

RECRUITING

WC45726 (0165/1298): PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL CLUSTER STUDY CLUSTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF WEEKLY ADMINISTRATION OF RO7795068 (CT-388) TO PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES.

MARITIME – CV

RECRUITING

A phase 3, randomized, double-blind, placebo-controlled study to evaluate the impact of Maridebart Cafraglutide on cardiovascular outcomes in participants living with overweight or obesity and atherosclerotic cardiovascular disease.

INCB 18424-309

RECRUITING

Phase 3, randomized, double-blind study on the efficacy and safety of ruxolitinib cream in children (ages ≥ 6 years to < 12 years) with non-segmental vitiligo.

EFC18241

RECRUITING

A phase 3, randomized, double-blind, 2-arm study to investigate the efficacy and safety of teplizumab compared to placebo in participants aged 1 to 25 years with newly diagnosed stage 3 type 1 diabetes (T1D)

kaiNETIC-2

RECRUITING

Protocol Number K9531-3104 Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Once-Weekly KAI-9531 in Participants with Diabetes Who Are Obese or Overweight.

CHESTNUT

RECRUITING

ALXN1850-HPP-303 A Phase 3, Randomized, Open-Label, Parallel-Group, Actively Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1850 Compared to Subcutaneously Administered Asfotase Alfa in Pediatric Participants (2 to <12 Years of Age) with Hypophosphatasia (HPP) Previously Treated with Asfotase Alfa

HICKORY

RECRUITING

ALXN1850-HPP-301 “A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneously administered ALXN1850 (Recombinant Alkaline Phosphatase) in adolescent (12 to <18 years of age) and adult participants with hypophosphatasia who have not been previously treated with Asfotase Alfa.”

MULBERRY

RECRUITING

ALXN1850-HPP-305 “Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of ALXN1850 vs. Subcutaneous Placebo Administration in Treatment-Negative Pediatric Participants (2 to <12 Years of Age) with Hypophosphatasia (HPP)”

C5091017

RECRUITING

Protocol C5091017: A Phase 3, Double-Blind, 2-Arm Efficacy and Safety Interventional Study to Investigate Orally Administered Ibuzatrelvir Compared to Placebo in Symptomatic Adult and Adolescent Non-Participants Hospitalized with COVID-19 Who Are at High Risk of Progressing to Severe Disease

Baxduo PACIFIC

RECRUITING

A phase III, randomized, double-blind, placebo-controlled, event-driven study to evaluate the efficacy, safety, and tolerability of Baxdrostat in combination with dapagliflozin compared to dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and elevated blood pressure

POSIBIL_ESKD

RECRUITING

A phase 2b/3, multicenter, randomized, double-blind, placebo-controlled, combined dose-determination and cardiovascular outcomes study to investigate the efficacy and safety of CSL300 (clazakizumab) in end-stage renal disease subjects on dialysis

ARIA – GSK 206867

RECRUITING

Phase 3, 24-week, randomized, double-blind, parallel-group, Bayesian dynamic model study to compare the efficacy, safety, tolerability, and pharmacokinetics of FF/UMEC/VI with that of FF/VI in participants aged 12 to 17 years with inadequately controlled asthma receiving stable maintenance therapy with ICS/LABA.

CALM Bellus

RECRUITING

A Phase 3, 12-Week, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study of BLU-5937 in Adult Participants With Refractory or Unexplained Chronic Cough (RCC) (CALM-1)

CBP-201-207

RECRUITING

Chronic Obstructive Pulmonary Disease (COPD)/CBP-201-207 A phase 2, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy and safety of rademikibart as add-on therapy for an acute exacerbation in participants with chronic obstructive pulmonary disease and type 2 inflammation.

Enith 1

RECRUITING

WC45725 (0165/1297): PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY. GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY ADMINISTRATION RO7795068 (CT-388) TO OVERWEIGHT OR OBESE PARTICIPANTS WITHOUT TYPE 2 DIABETES

BNT323-01

RECRUITING

Open-label trial of single-agent chemotherapy versus investigator-chosen chemotherapy in previously treated patients with recurrent or metastatic HER2-expressing endometrial cancer

DESTINY

RECRUITING

DS8201-724, Multicenter, randomized, open-label, phase 3 trial of trastuzumab deruxtecan (Enhertu®) plus chemotherapy plus or less pembrolizumab versus chemotherapy plus trastuzumab plus or less pembrolizumab as first-line treatment in participants with HER2-positive, locally advanced or metastatic unresectable gastric or gastroesophageal junction (GEJ) cancer (DESTINY-Gastric05)

DESTINY-Endometrial02 (DE-02)

RECRUITING

Full protocol title: Phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan versus standard treatment (carboplatin in combination with paclitaxel) as adjuvant treatment for HER2-expressing endometrial cancer (IHC 3+/IHC2+).

DS7300-203

RECRUITING

DS7300-203: An open-label, pan-tumoral phase 2 study to evaluate the efficacy and safety of Ifinatamab Deruxtecan (I-DXD) in subjects with recurrent or metastatic solid tumors.

BE-EARLY

RECRUITING

219240 “A phase 4, multicenter, prospective, open-label study describing the efficacy and safety of subcutaneously administered belimumab in adult participants with early-stage systemic lupus erythematosus”

EMERALD

RECRUITING

"A long-term, multicenter, randomized, blinded, phase 3 extension study to evaluate the safety and efficacy of BIIB059 in adult participants with active systemic lupus erythematosus (SLE)"

WA45846

RECRUITING

A PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO7790121 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO OR INTOLERANCE OF TNF AND/OR JAK INHIBITORS